Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab versus Rebif in relapsing-remitting multiple sclerosis after relapse on prior therapy
2007-001162-32Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alemtuzumab and interferon beta-1a in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Sanofi. Primary endpoints: Time to sustained accumulation of disability and Relapse rate. Started Oct 2007; status: completed.
02
Drugs
alemtuzumabinterferon beta-1a
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2007-001162-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001162-32.